Focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favorable – intermediate-risk prostate cancer

Not Applicable

• Conditions: ow or favorable – intermediate-risk prostate cancer; Cancer

• Registration Number: ISRCTN16325499
• Lead Sponsor: ational Cancer Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-29
• Last Update Posted: 9 January 2023
• Study Completion: 2032-09-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

1. Aged 40 to 75 years old
2. Multiparametric magnetic resonance tomography (mpMRI) was performed, and the tumor was verified by transrectal ultrasound (TRUS) – mpMRI fusion guided biopsy together with systemic biopsy
3. Histologically confirmed low- or favorable intermediate-risk PCa from mpMRI visible lesions only that meet the following criteria and there is no disease found in systemic biopsy (PSA = 10 ng/ml; ISUP = 2; T1 – T2b)
4. Less than 25 % of biopsies were affected
5. The size of the prostate does not exceed 60 cm3
6. Index lesion is larger than 0.5 cm3 or 6 mm in diameter
7. IPSS score is not greater than 18 points
8. Agrees to participate in the study and signs the consent form

Exclusion Criteria

1. Previous radical prostate cancer treatment
2. Proven extracapsular extension of disease
3. Metastatic tumors

Study & Design

• Study Type: Interventional
• Study Design: Not specified